Nicotine sensitizes the mouse brain to the addictive effects of cocaine, according to recent NIDA-supported research. The results accord with the hypothesis that a person’s initial use of an addictive substance physiologically sensitizes his or her brain to the rewarding and addictive effects of other substances. If the findings carry over to people, then preventing youths from smoking might reduce their vulnerability to cocaine abuse and addiction, and cocaine-dependent individuals might ease their path to recovery by quitting smoking.
While viewing images of cigarettes, smokers reported milder cravings when they shifted their focus from the pleasures of smoking to its harmful effects. Brain imaging showed a correlation between the reductions in craving and altered activity levels in regions associated with emotional regulation and reward.
April 2012 Dr. Volkow discusses NIDA’s efforts to develop effective antismoking treatments for populations with persistently high rates of smoking, such as people with psychiatric disorders, high school dropouts, and Native Americans.
April 2012 A program involving home visits by nurses to low-income first-time mothers, starting during pregnancy and extending into the second year of their children’s lives, has a positive and long-lasting impact on families. Children who participated in the program were less likely than others to report having used alcohol, cigarettes, or marijuana at age 12.
During early abstinence, smokers’ cravings triggered by cigarette cues intensified over time, providing evidence that people can experience a phenomenon previously observed in experiments with animals
New research suggests that differences in tobacco consumption reflect, in part, differences in the functional efficacy of a specific type of receptor in a pathway of the brain. In animal studies, nicotinic acetylcholine receptors with the α5 subunit played a key role in producing aversive responses to nicotine, thereby dissuading further consumption of the drug.
March 2012 Dr. Thomas Kosten of Baylor College of Medicine and Dr. Peter Burkhard of the University of Connecticut are the recipients of NIDA’s 2011 Avant-Garde Awards for Innovative Medication Development Research. Dr. Kosten is developing a vaccine against methamphetamine abuse and Dr. Burkhard is developing a vaccine to counter nicotine addiction.
July 2011 Describes research showing that the combination of prenatal smoking exposure and specific genes increases children’s and adolescent’s risk for behavior problems.
March 2011 Describes a community focused prevention program that aids towns in lowering rates of delinquency, initiation of alcohol and tobacco use, and binge drinking among middle school students.